Evidence map›Paper›PMID 42423928›Full record

ArticleInternational journal of clinical oncology2026

Preoperative prediction of vessels encapsulating tumor clusters in hepatocellular carcinoma based on CT findings and des-γ-carboxy prothrombin level.

Tomohiko Taniai, Koichiro Haruki, Megumi Shiraishi, Kenei Furukawa, Mitsuru Yanagaki, Kazutaka Gomisawa, Juha P Väyrynen, Yuto Yamahata, Munetoshi Akaoka, Masashi Tsunematsu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tomohiko TaniaiDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Koichiro HarukiDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan. haruki@jikei.ac.jp.ORCID http://orcid.org/0000-0002-1686-3228
Megumi ShiraishiDepartment of Radiology, The Jikei University School of Medicine, Tokyo, Japan.
Kenei FurukawaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Mitsuru YanagakiDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Kazutaka GomisawaDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Juha P VäyrynenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.
Yuto YamahataDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Munetoshi AkaokaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Masashi TsunematsuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Shinji OndaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Atsushi NaraDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Shinji TanakaDepartment of Molecular Oncology, Graduate School of Medicine, Institute of Science Tokyo, Tokyo, Japan.
Toru IkegamiDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.

Funding

Japanese Foundation for Multidisciplinary Treatment of Cancer Japanese Foundation for Multidisciplinary Treatment of CancerJapan Society for the Promotion of Science 23K15531Japan Society for the Promotion of Science 24K11898Japan Society for the Promotion of Science 24K11920Takeda Science Foundation Takeda Science Foundation
6 · The paper itself

Abstract

backgroundVessels encapsulating tumor clusters (VETC) has been associated with poor prognosis in hepatocellular carcinoma (HCC). However, the preoperative prediction of VETC remains insufficient. We established the VETC predictive score based on CT findings and clinical data in patients with HCC.

methodsA total of 209 patients were enrolled, and we investigated clinical features and computed tomography (CT) findings in patients with VETC-positive HCC. The preoperative VETC predictive score was established based on the odds ratios calculated by logistic regression analysis using identified predictive factors, and the accuracy of this score was investigated. The utility of VETC predictive score was validated in the validation cohort.

resultsVETC-positive HCC was associated with higher protein induced by des-γ-carboxy prothrombin (DCP) level (p = 0.03), larger tumor size (p < 0.01), intratumor necrosis (p < 0.01), and intratumor vessels (p < 0.01), and the VETC predictive score was established using these variables. The positive rate of VETC was significantly higher in the score-high group compared to the score-low group (60% vs. 27%, p < 0.01). Patients with high scores showed higher DCP level (p < 0.01), moderate/poor differentiation (p < 0.01), larger tumor (p < 0.01), microvascular invasion (p < 0.01), VETC-positivity (p < 0.01), lower densities of CD8

conclusionThe VETC predictive score based on CT and DCP is useful, and preoperative diagnosis of VETC may contribute to optimized treatment management for HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNeovascularization, PathologicProtein PrecursorsAgedBiomarkersBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisProthrombinTomography, X-Ray ComputedacarboxyprothrombinBiomarkersBiomarkers, TumorProtein PrecursorsProthrombinComputed tomographyHepatocellular carcinomaPredictive scoreTumor microenvironmentVessels encapsulating tumor clusters

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.